Diligence memo · auto-generated · as of July 3, 2026
Mirador Therapeutics, Inc.
Mirador Therapeutics, Inc. looks over-valued against its niche peers and is quiet on financing cadence.
Businessfiled
Mirador Therapeutics, Inc. operates in Pharma, based in San Diego.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Mirador Therapeutics, Inc. has raised $413M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $333M on 2024-02-15.
Most recent recorded round closed around 2024-02-15.
Valuation (modeled)modeled
Provath models Mirador Therapeutics, Inc. at approximately $4.0B (range $1.6B–$5.8B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.95× the median modeled value of Series D+ Pharma companies in 2022–2024 (7 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 2 months.
Last raise 2.4 yr ago; this sector typically re-raises about every 16 months.
Slightly overdue versus sector cadence.
The last round stepped up 4.2× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 100% of Pharma peers (310 compared).
Modeled value ranks above 98% of those peers.
Closest niche peers: Autolus Therapeutics plc, Candid Therapeutics, Inc., Bluejay Therapeutics, Inc., Halda Therapeutics, LLC, Bright Peak Therapeutics, Inc..
Peoplefiled
8 named people on file across officers, directors and signatories.
Risks & flagsmixed
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.